# A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

> **NCT04183686** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 88 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ACT-1014-6470 (SAD)
- **DRUG:** ACT-1014-6470 (MAD)
- **DRUG:** Placebo (SAD)
- **DRUG:** Placebo (MAD)
- **DRUG:** 14C-ACT-1014-6470 microtracer
- **DRUG:** 14C-ACT-1014-6470 microtracer placebo

## Key facts

- **NCT ID:** NCT04183686
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-25
- **Primary completion:** 2020-03-15
- **Final completion:** 2020-03-15
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183686, "A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04183686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*